Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 4;12(1):2163785. doi: 10.1080/2162402X.2022.2163785

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — T cell responses after BNT162b2 injections in patients with HM. a. Experimental setting for the in vitro stimulation (IVS) assay based on 22 peptides. b. Heatmap representing cytokine release (IFNγ (red) and IL5 (blue)) detected in IVS assay (a) from PBMC drawn at visits 1, 3, 4 and 5 and stimulated with a pool of wild-type or mutant S1-RBD peptides (Table S1). Results are shown according to HM type, therapy, time and intensity of the response (the color gradient is proportional to the quantity of IFNγ or IL-5 release). c. Idem as in B but showing the reactivity to single peptide contained in the pool as a percentage of reactive patients who developed a S1-RBD specific IFNγ (red) or IL-5 (blue) cytokine release for wild-type and mutant epitopes. d. Experimental setting for the whole-blood automatic stimulation assay. e. Head-on comparison of paired specimen analyzed with the classical (A) or the automatic Vidas assay (d). The percentage of patients who developed IFNγ reactivity to wild-type and mutant peptides using the two different techniques is depicted. The threshold for IFNγ positivity is ≥ 10 pg/mL for in vitro stimulation assay and ≥ 0.08 UI/mL for whole blood assay. f. Analysis of the effects of the booster on humoral and cellular immune responses directed against S1-RBD, by the percentages of positive patients. Student t-test or ANOVA Fischer exact method.